Skip to content

King Pharmaceuticals KG Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

SiriusPoint logo
SiriusPointSPNT
$23.3M-3.7%
W.R. Berkley logo
W.R. BerkleyWRB
$255.72M+14.7%
Silvercrest Asset Management Group logo
Silvercrest Asset Management GroupSAMG
$18.25M-13.2%
Lazard logo
LazardLAZ
$472.58M-6.2%

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M
Total equity$121.4M+2,773%
Total assets$964.2M

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-71.3%
Enterprise value$184.93M-52.3%
P/E1.2×
P/S1.6×-27.7×

Profitability

See full
Net margin131.5%

Returns & leverage

See full
Return on equity90.8%
Debt / equity1.5×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's operating lease liabilities (total)?
King Pharmaceuticals (KG) reported operating lease liabilities (total) of $2M in Q1 2026.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.